ADMA Biologics Inc
NASDAQ:ADMA

Watchlist Manager
ADMA Biologics Inc Logo
ADMA Biologics Inc
NASDAQ:ADMA
Watchlist
Price: 17.8 USD -3.78% Market Closed
Market Cap: 4.2B USD
Have any thoughts about
ADMA Biologics Inc?
Write Note

P/E
Price to Earnings

21.3
Current
-7.7
Median
21.6
Industry
Higher than median
Lower than industry value

Price to Earnings (P/E) ratio is a valuation multiple that compares a company’s market capitalization to its net income. It indicates the dollar amount an investor can expect to invest in a company in order to receive $1 of that company’s earnings.

P/E
21.3
=
Market Cap
4.2B USD
/
Net Income
197.7m USD
All Countries
Close
Earnings Growth PEG
US
ADMA Biologics Inc
NASDAQ:ADMA
Average P/E: 75.9
21.3
12%
1.8
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -173 234.4 N/A N/A
US
Abbvie Inc
NYSE:ABBV
88.4
88%
1
US
Amgen Inc
NASDAQ:AMGN
41.2
44%
0.9
US
Gilead Sciences Inc
NASDAQ:GILD
293.6
185%
1.6
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Negative Multiple: -241.2 N/A N/A
US
E
Epizyme Inc
F:EPE
Negative Multiple: -493.2 N/A N/A
AU
CSL Ltd
ASX:CSL
27.7
16%
1.7
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
17
11%
1.5
US
S
Seagen Inc
F:SGT
Negative Multiple: -57.1 N/A N/A
NL
argenx SE
XBRU:ARGX
42.3
19%
2.2

P/E Forward Multiples

Forward P/E multiple is a version of the P/E ratio that uses forecasted net income for the P/E calculation. 1-Year, 2-Years, and 3-Years forwards use net income forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
P/E
25.2
2-Years Forward
P/E
18.9
3-Years Forward
P/E
15.1